SOUTH SAN FRANCISCO, Calif.,
Nov. 5, 2021 /PRNewswire/ -- Titan
Pharmaceuticals, Inc. announced that data from continuing studies
of its ProNeura®-based TP-2021 implant in an established
animal model of chronic pruritus will be presented at the Society
for Neuroscience 2021 Meeting, being held virtually, on
November 8.
About Chronic Pruritus
Chronic pruritus is an unpleasant and often debilitating
condition, resulting in the need to scratch that lasts more than 6
weeks. It is a prevalent and potentially debilitating symptom
associated with both cutaneous and systemic conditions. Due to its
complex pathogenesis and numerous contributing factors, effective
treatment of chronic pruritus therapy remains challenging.
About Titan
Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), based in
South San Francisco, CA, is a
development stage company developing proprietary therapeutics with
its ProNeura® long-term, continuous drug delivery
technology. The ProNeura technology has the potential to be used in
developing products for treating a number of chronic conditions,
where maintaining consistent, around-the-clock blood levels of
medication may benefit the patient and improve medical outcomes.
For more information about Titan, please
visit www.titanpharm.com.
Forward-Looking
Statements
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
product development programs and any other statements that are not
historical facts. Such statements involve risks and uncertainties
that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause
actual results to differ materially from management's current
expectations include those risks and uncertainties relating to our
ability to raise capital, the regulatory approval process, the
development, testing, production and marketing of our drug
candidates, patent and intellectual property matters and strategic
agreements and relationships. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
CONTACT:
Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/titan-announces-upcoming-tp-2021-implant-data-presentation-at-neuroscience-2021-301417786.html
SOURCE Titan Pharmaceuticals, Inc.